Patents Assigned to Alphavax, Inc.
-
Patent number: 10570416Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: GrantFiled: August 11, 2016Date of Patent: February 25, 2020Assignee: ALPHAVAX, INC.Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
-
Patent number: 10111943Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.Type: GrantFiled: June 29, 2016Date of Patent: October 30, 2018Assignee: ALPHAVAX, INC.Inventors: Jonathan F. Smith, Bolyn Hubby, Laura Copp
-
Patent number: 9597414Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.Type: GrantFiled: February 5, 2014Date of Patent: March 21, 2017Assignee: ALPHAVAX, INC.Inventors: Vernon McNeil Coffield, III, Kurt I. Kamrud, Jonathan F. Smith
-
Patent number: 9441247Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: GrantFiled: July 6, 2015Date of Patent: September 13, 2016Assignee: ALPHAVAX, INC.Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
-
Patent number: 9416370Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.Type: GrantFiled: October 18, 2010Date of Patent: August 16, 2016Assignee: AlphaVax, Inc.Inventors: Jonathan F. Smith, Bolyn Hubby, Laura Copp
-
Patent number: 9187729Abstract: Disclosed are methods for preparing dried (preferably lyophilized) preparations comprising a population of alphaviruses or alphavirus replicon particles, a sugar or polyol, a surfactant and a salt and preparations made by these methods, both in the dried form but also as liquids prior to drying or after reconstituting dried preparations. These preparations may further comprise a plasticizer and/or a bulking agent. These preparations are readily reconstituted, with little or no loss in infectivity of the viruses or replicon particles.Type: GrantFiled: January 24, 2011Date of Patent: November 17, 2015Assignee: ALPHAVAX, INC.Inventors: Roberto A. DePaz, Todd L. Talarico
-
Patent number: 9079943Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: GrantFiled: March 28, 2014Date of Patent: July 14, 2015Assignee: ALPHAVAX, INC.Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
-
Publication number: 20140308312Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.Type: ApplicationFiled: February 5, 2014Publication date: October 16, 2014Applicant: ALPHAVAX, INC.Inventors: Vernon McNeil Coffield, III, Kurt I. Kamrud, Jonathan F. Smith
-
Publication number: 20140205629Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: ApplicationFiled: March 28, 2014Publication date: July 24, 2014Applicant: AlphaVax, Inc.Inventors: Jon O. RAYNER, Jonathan F. SMITH, Bolyn HUBBY, Elizabeth A. REAP
-
Patent number: 8709441Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: GrantFiled: July 6, 2010Date of Patent: April 29, 2014Assignee: Alphavax, Inc.Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
-
Patent number: 8680258Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.Type: GrantFiled: November 25, 2009Date of Patent: March 25, 2014Assignee: Alphavax, Inc.Inventors: Vernon McNeil Coffield, Kurt I. Kamrud, Jonathan F. Smith
-
Patent number: 8617533Abstract: Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic acid library can be a random library, or it can be prepared after a selection step, for example, by differential hybridization prior to cloning into the replicon vector.Type: GrantFiled: May 6, 2008Date of Patent: December 31, 2013Assignee: AlphaVax, Inc.Inventors: Jonathan F. Smith, Kurt Kamrud, Sergey Dryga, Ian Caley
-
Patent number: 8263092Abstract: The immune response to an antigen of interest, either in purified form or expressed via an alphavirus replicon particle, can be enhanced by the simultaneous administration of an alphavirus replicon particle which expresses interleukin-12. This allows for the use of significantly smaller quantities of the antigen and this immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.Type: GrantFiled: September 12, 2007Date of Patent: September 11, 2012Assignee: AlphaVax, Inc.Inventors: Jonathan F. Smith, Bolyn Hubby, Peter Berglund, Laura Copp, Whitney Ellis
-
Publication number: 20120213813Abstract: The immune response to an antigen of interest, either in purified form or expressed via an alphavirus replicon particle, can be enhanced by the simultaneous administration of an alphavirus replicon particle which expresses interleukin-12. This allows for the use of significantly smaller quantities of the antigen and this immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.Type: ApplicationFiled: September 12, 2007Publication date: August 23, 2012Applicant: AlphaVax, Inc.Inventors: Jonathan F. Smith, Bolyn Hubby, Peter Berglund, Laura Copp, Whitney Ellis
-
Publication number: 20120100179Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.Type: ApplicationFiled: November 25, 2009Publication date: April 26, 2012Applicant: ALPHAVAX, INC.Inventors: Vernon McNeil Coffield, Kurt I. Kamrud, Jonathan F. Smith
-
Publication number: 20110182941Abstract: Disclosed are methods for preparing dried (preferably lyophilized) preparations comprising a population of alphaviruses or alphavirus replicon particles, a sugar or polyol, a surfactant and a salt and preparations made by these methods, both in the dried form but also as liquids prior to drying or after reconstituting dried preparations. These preparations may further comprise a plasticizer and/or a bulking agent. These preparations are readily reconstituted, with little or no loss in infectivity of the viruses or replicon particles.Type: ApplicationFiled: January 24, 2011Publication date: July 28, 2011Applicant: AlphaVax, Inc.Inventors: Roberto A. DePaz, Todd L. Talarico
-
Publication number: 20110086062Abstract: The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen.Type: ApplicationFiled: October 18, 2010Publication date: April 14, 2011Applicant: AlphaVax, Inc.Inventors: Jonathan F. Smith, Bolyn Hubby, Laura Copp
-
Publication number: 20110027306Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: ApplicationFiled: July 6, 2010Publication date: February 3, 2011Applicant: AlphaVax, Inc.Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
-
Patent number: 7850977Abstract: The present invention provides an isolated RNA molecule comprising: a) an alphavirus 5? replication recognition sequence, wherein at least one initiation codon has been removed from the 5? replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3? replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5? and 3? replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus nonstructural proteins.Type: GrantFiled: June 20, 2008Date of Patent: December 14, 2010Assignee: Alphavax, Inc.Inventors: Kurt I. Kamrud, Jonathan F. Smith, Maureen Maughan
-
Publication number: 20090047255Abstract: Disclosed are methods for preparing dried (preferably lyophilized) preparations comprising a population of alphaviruses or alphavirus replicon particles, a sugar or polyol, a surfactant and a salt and preparations made by said methods, both in the dried form but also as liquids prior to drying or after reconstituting dried preparations. These preparations may further comprise a plasticizer and/or a bulking agent. These preparations are readily reconstituted, with little or no loss in infectivity of the viruses or replicon particles.Type: ApplicationFiled: November 2, 2007Publication date: February 19, 2009Applicant: AlphaVax, Inc.Inventors: Roberto A. DePaz, Todd L. Talarico